Greenphire Launches Research Registry App
Greenphirehas unveiled the addition of the Patient-Powered Registry, designed to help foundations more effectively engage and support patient communities.
The mobile and web-based registry will allow disease-specific organizations to communicate with members—delivering patient insights such as condition-specific health information, employing interactive tools such as virtual surveys, and connecting and matching members with clinical trials that they may be interested in. Foundations can create and manage registry content quickly, streamlining operations and improving analytics to enhance patient support and provide value-added data to key stakeholders such as their boards of directors.
For patients, the Patient-Powered Registry allows them to receive trusted information on their disease, enables them to join others with the same diagnosis in driving research, and provides the flexibility to share information, such as treatments they are participating in and symptoms, in real-time.
The Patient-Powered Registry allows foundations to become even more valuable partners to sponsors by providing foundations with a tool to facilitate connections between sponsors and participants in clinical trials. In addition, it allows them to identify potential participants based on their medical history, geographic location, and other criteria.
Reference
Greenphire Launches Research Registry App Allowing Foundations and Advocacy Groups to Better Engage and Support Patient Communities. (2023, March 21). Cision PR Newswire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
